Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $2.0 million.

  • Abvc Biopharma's Operating Expenses rose 18415.61% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 1590.52%. This contributed to the annual value of $5.2 million for FY2024, which is 2120.34% down from last year.
  • Latest data reveals that Abvc Biopharma reported Operating Expenses of $2.0 million as of Q3 2025, which was up 18415.61% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Operating Expenses peaked at $6.4 million during Q4 2021, and registered a low of $374794.0 during Q4 2023.
  • In the last 5 years, Abvc Biopharma's Operating Expenses had a median value of $2.1 million in 2021 and averaged $2.3 million.
  • In the last 5 years, Abvc Biopharma's Operating Expenses surged by 31214.04% in 2022 and then crashed by 8915.71% in 2023.
  • Quarter analysis of 5 years shows Abvc Biopharma's Operating Expenses stood at $6.4 million in 2021, then tumbled by 46.05% to $3.5 million in 2022, then crashed by 89.16% to $374794.0 in 2023, then surged by 88.51% to $706530.0 in 2024, then surged by 178.03% to $2.0 million in 2025.
  • Its Operating Expenses stands at $2.0 million for Q3 2025, versus $2.3 million for Q2 2025 and $693005.0 for Q1 2025.